Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Ronald Reagan University of California Los Angeles Medical Center

2 abstracts

Abstract
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.
Org: Dana-Farber Cancer Institute, Institut Català D'Oncologia, Leiden University Medical Center, Rigshospitalet, Copenhagen University Hospital, Ronald Reagan University of California Los Angeles Medical Center,
Abstract
Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.
Org: Lymphoma Service, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Vejle Hospital, Universitair Ziekenhuis Gent, Ronald Reagan University of California Los Angeles Medical Center,